{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Biodesix, Inc.
Is Biodesix, Inc. technically bullish or bearish?
As of June 9, 2025, the market trend has shifted to a bearish stance, supported by daily moving averages, weekly KST, and Bollinger Bands, despite some mildly bullish signals from the MACD.
Who are in the management team of Biodesix, Inc.?
As of March 2022, the management team of Biodesix, Inc. includes Mr. Robert Cawthorn as Chairman of the Board and Mr. David Brunel as Chief Executive Officer and Director.
What does Biodesix, Inc. do?
Biodesix, Inc. is a U.S. company that develops blood-based diagnostic tests for oncology, classified as a micro-cap with a market cap of $41.70 million. As of March 2025, it reported net sales of $18 million and a net loss of $11 million.
How big is Biodesix, Inc.?
As of Jun 18, Biodesix, Inc. has a market capitalization of 41.70 million, with net sales of 74.47 million and a net profit loss of 40.42 million over the last four quarters. Shareholder's funds are 20.88 million, and total assets are 99.18 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
